Why is Sandu Pharmaceuticals Ltd falling/rising?

Recent Price Movement and Market Context

Sandu Pharmaceuticals’ stock has been under pressure, trading close to its 52-week low of ₹36.76, just 1.61% away as of the latest close. The stock’s intraday low touched ₹36.88, marking a 4.8% decline during the session. Notably, the weighted average price indicates that a larger volume of shares exchanged hands near the day’s low, signalling selling pressure. Furthermore, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring a bearish technical trend.

Investor participation has increased, with delivery volumes on 30 Dec surging by 632.97% compared to the five-day average, suggesting heightened activity but predominantly on the sell side given the price decline. Despite adequate liquidity for trading, the stock’s performance today lagged behind its sector by 4.69%, further emphasising its relative weakness.

Long-Term Performance and Fundamental Weaknesses

Over the past year, Sandu Pharmaceuticals has delivered a negative return of 34.63%, starkly contrasting with the Sensex’s positive 9.06% gain over the same period. This underperformance extends over longer horizons, with the stock declining 44.05% over three years while the Sensex surged 40.07%. Even over five years, the stock has lagged significantly, falling 11.51% compared to the benchmark’s 78.47% rise. Such persistent underperformance highlights structural challenges within the company and its market positioning.

Fundamentally, the company exhibits weak long-term growth metrics. Its average return on equity (ROE) stands at a modest 3.73%, indicating limited profitability relative to shareholder equity. Net sales have grown at an annual rate of just 4.69% over the last five years, while operating profit has increased by 17.92% annually, figures that suggest sluggish expansion in a competitive pharmaceutical sector. Additionally, the company’s ability to service debt is concerning, with an average EBIT to interest ratio of only 1.92, signalling potential financial strain.

Recent quarterly results have been flat, with net sales reported at a low ₹14.07 crore in March 2025, reinforcing the narrative of subdued operational momentum. Despite a 10.9% rise in profits over the past year, the stock’s price-to-earnings growth (PEG) ratio of 2.1 suggests that earnings growth is not sufficiently robust to justify current valuations.

Valuation and Shareholder Composition

On a valuation basis, Sandu Pharmaceuticals trades at a price-to-book value of 0.9, which is attractive relative to its peers’ historical averages. This discount reflects market scepticism about the company’s growth prospects and financial health. The majority of shareholders are non-institutional, which may contribute to volatility and less stable investor support compared to stocks with strong institutional backing.

Conclusion: Why the Stock is Falling

The decline in Sandu Pharmaceuticals’ share price is primarily driven by its weak fundamental performance, persistent underperformance against market benchmarks, and technical indicators signalling bearish momentum. Despite some profit growth, the company’s modest ROE, slow sales expansion, and limited debt servicing capacity weigh heavily on investor confidence. The stock’s proximity to its 52-week low and trading below all major moving averages further reinforce the negative sentiment.

Investors appear cautious, as reflected in the increased delivery volumes near the day’s low price, suggesting selling pressure. The lack of institutional shareholder support and flat recent quarterly results add to the concerns. While the valuation discount may attract value investors, the overall outlook remains subdued given the company’s inability to keep pace with sector and benchmark indices.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →